

## *Amendments*

### **In the Specification:**

Please replace paragraph [001] with the following amended paragraph:

[001] This application is entitled to and claims priority benefit to U.S. provisional application Serial No. 60/273,098, filed March 2, 2001, U.S. provisional application Serial No. 60/316,321, filed August 31, 2001, U.S. provisional application 60/346,918, filed October 19, 2001, and U.S. provisional application Serial No. ~~60/358,424~~, filed February 19, 2002, each of which is incorporated herein by reference in their entirety.

Please replace paragraph [0011] with the following amended paragraph:

[0011] The present invention is based, in part, on the recognition that integrin  $\alpha_v\beta_3$  antagonists potentiate and synergize with certain anti-inflammatory treatments including, in particular, anti-TNF- $\alpha$  agents and methotrexate. Thus, the invention encompasses treatment protocols that provide better prophylactic and therapeutic profiles than current single agent therapies for autoimmune and/or inflammatory disorders. The invention provides combination therapies for prevention, treatment or amelioration of one or more symptoms associated with an autoimmune or inflammatory disorder in a subject, said combination therapies comprising administering to said subject one or more integrin  $\alpha_v\beta_3$  antagonists and one or more prophylactic or therapeutic agents other than integrin  $\alpha_v\beta_3$  antagonists. In particular, the invention provides combination therapies for prevention, treatment or amelioration of one or more symptoms associated with an autoimmune or inflammatory disorder in a subject, said combination therapies comprising administering to said subject an integrin  $\alpha_v\beta_3$  antagonist, preferably VITAXIN™ (etaracizumab), and at least one other prophylactic or therapeutic agent which has a different mechanism of action than the integrin  $\alpha_v\beta_3$  antagonist.